- Home
- PENG vs GERN Comparison
PENG vs GERN Comparison
Compare PENG & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PENG
- GERN
- Stock Information
- Founded
- PENG 1988
- GERN 1990
- Country
- PENG Cayman Islands
- GERN United States
- Employees
- PENG N/A
- GERN N/A
- Industry
- PENG Semiconductors
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- PENG Technology
- GERN Health Care
- Exchange
- PENG Nasdaq
- GERN Nasdaq
- Market Cap
- PENG 912.5M
- GERN 853.5M
- IPO Year
- PENG 2017
- GERN 1996
- Fundamental
- Price
- PENG $17.76
- GERN $1.57
- Analyst Decision
- PENG Strong Buy
- GERN Buy
- Analyst Count
- PENG 8
- GERN 9
- Target Price
- PENG $24.94
- GERN $5.13
- AVG Volume (30 Days)
- PENG 571.6K
- GERN 13.0M
- Earning Date
- PENG 07-08-2025
- GERN 05-07-2025
- Dividend Yield
- PENG N/A
- GERN N/A
- EPS Growth
- PENG N/A
- GERN N/A
- EPS
- PENG N/A
- GERN N/A
- Revenue
- PENG $1,318,349,000.00
- GERN $116,293,000.00
- Revenue This Year
- PENG $19.66
- GERN $160.12
- Revenue Next Year
- PENG $8.64
- GERN $55.01
- P/E Ratio
- PENG N/A
- GERN N/A
- Revenue Growth
- PENG 8.05
- GERN 22264.04
- 52 Week Low
- PENG $14.20
- GERN $1.17
- 52 Week High
- PENG $29.81
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- PENG N/A
- GERN 51.71
- Support Level
- PENG N/A
- GERN $1.30
- Resistance Level
- PENG N/A
- GERN $1.54
- Average True Range (ATR)
- PENG 0.00
- GERN 0.11
- MACD
- PENG 0.00
- GERN 0.03
- Stochastic Oscillator
- PENG 0.00
- GERN 66.67
About PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.